The immunology and neuropathology of the autoimmune nodopathies
Johnson CB. et al, (2025), Journal of Neuroimmunology, 406
Real-World Multinational Survey of Chronic Inflammatory Demyelinating Polyneuropathy: Disease Characteristics and Therapeutic Landscape
Querol L. et al, (2025), Journal of the Peripheral Nervous System, 30
Diagnosis and Management of Multifocal Motor Neuropathy in the United Kingdom: A Multicentre Survey.
Rajabally YA. et al, (2025), J Peripher Nerv Syst, 30
Inter-Laboratory Validation of Nodal/Paranodal Antibody Testing.
Lleixà C. et al, (2025), J Peripher Nerv Syst, 30
Case Report: Pediatric age onset CNTN1 antibody-associated neuropathy with nephropathy and literature review.
Bayraktar Eltutan C. et al, (2025), Front Immunol, 16
Electrodiagnostic subtyping in Guillain-Barré syndrome patients in the International Guillain-Barré Outcome Study.
Arends S. et al, (2024), Eur J Neurol, 31
Combined central and peripheral demyelination in two siblings, immune mediated or genetic?
Moodley K. et al, (2024), Pract Neurol
Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
Keddie S. et al, (2023), Brain, 146, 4562 - 4573
Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease.
Bellanti R. et al, (2023), J Neurol Neurosurg Psychiatry
Nodal-paranodal antibodies in HIV-immune mediated radiculo-neuropathies: Clinical phenotypes and relevance.
Moodley K. et al, (2023), J Peripher Nerv Syst
Reply: Peripherin is a biomarker of axonal damage in Guillain Barré syndrome: a pathophysiological annotation.
Keddie S. et al, (2023), Brain
AL amyloidosis presenting with isolated lumbosacral radiculoplexus neuropathy.
Bellanti R. et al, (2023), Pract Neurol